기업 비교

소개

Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.

매출

$52.8B

뉴스 갭 신호

기관 신호

캐스케이드 패턴

핵심 관계

소개

Novo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.

매출

$42.6B

뉴스 갭 신호

기관 신호

캐스케이드 패턴

핵심 관계